Akoya Biosciences, Inc.

NasdaqGS:AKYA Rapport sur les actions

Capitalisation boursière : US$105.1m

Akoya Biosciences Croissance future

Future contrôle des critères 1/6

Akoya Biosciences devrait augmenter ses bénéfices et ses revenus de 28.3% et de 9% par an respectivement, tandis que le BPA devrait croître de croître de 32.5% par an.

Informations clés

28.3%

Taux de croissance des bénéfices

32.5%

Taux de croissance du BPA

Life Sciences croissance des bénéfices18.3%
Taux de croissance des recettes9.0%
Rendement futur des capitaux propresn/a
Couverture par les analystes

Good

Dernière mise à jour18 Nov 2024

Mises à jour récentes de la croissance future

Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported, And Analysts Assigned A US$5.42 Price Target

Aug 09
Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported, And Analysts Assigned A US$5.42 Price Target

Recent updates

Revenue Downgrade: Here's What Analysts Forecast For Akoya Biosciences, Inc. (NASDAQ:AKYA)

Nov 19
Revenue Downgrade: Here's What Analysts Forecast For Akoya Biosciences, Inc. (NASDAQ:AKYA)

Is Akoya Biosciences (NASDAQ:AKYA) Using Too Much Debt?

Nov 12
Is Akoya Biosciences (NASDAQ:AKYA) Using Too Much Debt?

Akoya Biosciences, Inc. (NASDAQ:AKYA) Stock Rockets 36% But Many Are Still Ignoring The Company

Oct 08
Akoya Biosciences, Inc. (NASDAQ:AKYA) Stock Rockets 36% But Many Are Still Ignoring The Company

Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported, And Analysts Assigned A US$5.42 Price Target

Aug 09
Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported, And Analysts Assigned A US$5.42 Price Target

Market Might Still Lack Some Conviction On Akoya Biosciences, Inc. (NASDAQ:AKYA) Even After 31% Share Price Boost

Jun 27
Market Might Still Lack Some Conviction On Akoya Biosciences, Inc. (NASDAQ:AKYA) Even After 31% Share Price Boost

Is Akoya Biosciences (NASDAQ:AKYA) A Risky Investment?

Jun 24
Is Akoya Biosciences (NASDAQ:AKYA) A Risky Investment?

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Akoya Biosciences, Inc.'s (NASDAQ:AKYA) CEO For Now

May 29
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Akoya Biosciences, Inc.'s (NASDAQ:AKYA) CEO For Now

Investors Continue Waiting On Sidelines For Akoya Biosciences, Inc. (NASDAQ:AKYA)

May 10
Investors Continue Waiting On Sidelines For Akoya Biosciences, Inc. (NASDAQ:AKYA)

Is Akoya Biosciences (NASDAQ:AKYA) Weighed On By Its Debt Load?

Feb 28
Is Akoya Biosciences (NASDAQ:AKYA) Weighed On By Its Debt Load?

Investors Still Aren't Entirely Convinced By Akoya Biosciences, Inc.'s (NASDAQ:AKYA) Revenues Despite 31% Price Jump

Nov 25
Investors Still Aren't Entirely Convinced By Akoya Biosciences, Inc.'s (NASDAQ:AKYA) Revenues Despite 31% Price Jump

Akoya Biosciences Seeks Growth Despite Higher Operating Losses

May 30

Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 11
Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Prévisions de croissance des bénéfices et des revenus

NasdaqGS:AKYA - Estimations futures des analystes et données financières antérieures (USD Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/2026106-24-17-67
12/31/202591-32-16-97
12/31/202482-56-43-437
9/30/202487-58-49-47N/A
6/30/202493-60-54-51N/A
3/31/202494-68-56-52N/A
12/31/202397-63-55-51N/A
9/30/202391-71-59-55N/A
6/30/202385-76-61-54N/A
3/31/202379-73-62-55N/A
12/31/202275-71-61-53N/A
9/30/202270-69-57-49N/A
6/30/202264-63-57-51N/A
3/31/202260-51-55-50N/A
12/31/202155-44-41-36N/A
9/30/202152-34-37-32N/A
6/30/202148-28-24-21N/A
3/31/202144-28-13-10N/A
12/31/202042-22-10-7N/A
12/31/201942-18-17-14N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: AKYA devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: AKYA devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: AKYA devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de AKYA ( 9% par an) devrait croître plus rapidement que le marché US ( 9% par an).

Croissance élevée des revenus: Le chiffre d'affaires de AKYA ( 9% par an) devrait croître plus lentement que 20% par an.


Prévisions de croissance du bénéfice par action


Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de AKYA devrait être élevé dans 3 ans


Découvrir les entreprises en croissance